Current Report · Items 5.07 · 8-K

Compass Therapeutics, Inc.

CMPXNASDAQEQUITYCurrent

Submission of Matters to a Vote of Security Holders

Filed Jun 11, 2026Accepted Jun 11, 2026, 4:00 PM EDTCIK 1738021Accession 0001171843-26-004068

Company context

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts.

Current securities

CMPXNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 5.07

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 10, 2026 Compass Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. The final results for each of the matters submitted to a vote of stockholders at the meeting are set forth below. A more detailed description of each proposal is set forth in the Company’s definitive proxy statement on Form DEF 14A, filed with the U.S. Securities and Exchange Commission on April 29, 2026. Proposal No. 1. Election of Directors. The stockholders elected the two Class III nominees for director to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth in the table below: Name For Withheld Broker Non-votes ────────────────────────────────────────────────────────────────────────────────────────── Thomas J. Schuetz, M.D., Ph. D. 102,984,184 18,837,499 21,320,318 Richard S. Lindahl, M.B.A. 103,453,540 18,368,143 21,320,318 Proposal No. 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the votes set forth in the table below: For Against Withheld Broker Non-votes ───────────────────────────────────────────────────────────────── 137,896,097 181,037 5,064,867 - Proposal No. 3. Non-binding, Advisory Vote on the Compensation of our Named Executive Officers. The stockholders voted to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, by the votes set forth in the table below: For Against Abstain Broker Non-votes ─────────────────────────────────────────────────────────────────── 117,963,684 1,796,022 2,061,977 21,320,318 Proposal No. 4. Non-binding, Advisory Vote on the Holding of the Future Advisory Votes on the Compensation of our Named Executive Officers. The stockholders voted, on a non-binding, advisory basis, to hold such advisory votes annually, by the votes set forth in the table below: Every Year Every Two Years Every Three Years Abstain ────────────────────────────────────────────────────────────────────────── 118,289,260 811,275 1,491,631 1,229,517 Based on the voting results at the Annual Meeting, and consistent with the recommendation of the board of directors as set forth in our proxy statement for the Annual Meeting, the board of directors has determined to provide for a stockholder advisory vote on executive compensation on an annual basis; provided that, in the future, the board of directors may determine whether a different frequency for such advisory votes is in the best interests of the Company’s stockholders.